DDInter1590 DDInter1376
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Rifampicin {u} (Compound) resembles {v} (Compound) Rifabutin
Rifampicin {u} (Compound) treats {v} (Disease) leprosy
Rifampicin {u} (Compound) binds {v} (Gene) ABCC2
Rifampicin {u} (Compound) is included by {v} (Pharmacologic Class) Rifamycins
Rifampicin {u} (Compound) downregulates {v} (Gene) TIMP1
Rifampicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxepin
Rifampicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aluminum hydroxide
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Elagolix
Rifampicin (Compound) resembles Rifabutin (Compound)
Rifampicin (Compound) treats leprosy (Disease)
Rifampicin (Compound) binds ABCC2 (Gene)
Rifampicin (Compound) is included by Rifamycins (Pharmacologic Class)
Rifampicin (Compound) downregulates TIMP1 (Gene)
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Doxepin
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Rifampicin may lead to a major life threatening interaction when taken with Elagolix